Nutromics, a wearable molecular-sensing company based in Melbourne and San Diego, said on 11 September that the US Food and Drug Administration has granted Breakthrough Device Designation to its Vancomycin TDM Patch. The microneedle wearable is designed to track levels of the antibiotic vancomycin continuously, instead of through intermittent blood draws. Nutromics is aiming for a US launch in 2027, subject to regulatory authorisation. For now the patch is for investigational use only and has not been authorised for commercial distribution.

What the FDA recognised

Breakthrough designation is not a clearance. It gives developers of devices for serious conditions closer engagement with the agency on the route to a submission. According to Nutromics, the FDA weighed the device’s workflow improvements, increased accessibility and expected ability to return actionable results. It also considered the patch’s potential to support changes to vancomycin dosing sooner than the current standard of care allows.

“Our team is thrilled that the FDA has recognized our patch as a breakthrough technology and has committed to work closely with us on our pivotal study design and submission,” said Peter Vranes, chief executive and co-founder. That phrasing is also a reminder that the pivotal study has not yet been run.

Why vancomycin

Vancomycin treats life-threatening conditions including sepsis, and about 2.9 million patients in the US receive it each year, the company says. Getting the dose right is difficult. Medical Device Network notes that the current standard of care emphasises dosing guided by area under the curve (AUC), which estimates drug exposure over time, instead of relying only on trough levels. A continuous readout is aimed squarely at that problem.

“Vancomycin dosing for individualized patients is incredibly challenging to get right,” said Dr George Chiampas, an emergency medicine physician at Northwestern Hospital, in the company’s announcement. MedCity News reports that about 20% of ICU patients suffer vancomycin-induced acute kidney injury. We have not seen the underlying study for that figure.

How the patch works

The patch carries minimally invasive microneedles coated with synthetic DNA-based sensors. Vranes told MedCity News that the sensors “identify the target they are sensing and bind with it by folding”. Once the patch is applied to a patient’s arm, that binding produces an electrical signal. The signal is converted into drug-level measurements and sent over Bluetooth to hospital screens.

For the flexible and printed electronics supply chain, the interest lies in the platform more than the single drug. Electrochemical aptamer sensors on a skin-worn patch are one route to extending continuous wearable sensing beyond glucose to other molecules. Nutromics says multi-analyte sensing is its next step, with planned sensors for the diagnosis and management of sepsis and cardiovascular disease. The company has not said how the patch or its electrodes are manufactured, and we found no published data on how long a sensor lasts on skin.

The evidence so far

First-in-human data were published in Nature Biotechnology in February 2026, in a paper titled “Pilot phase clinical trial of a wearable, electrochemical aptamer-based patch for continuous drug concentration measurement”. Nutromics says it has since completed ICU clinical studies in Australia and is preparing further studies in the US. We have not read the full paper, and we could not find published results from the ICU studies. How closely the patch tracks blood-drawn vancomycin levels in critically ill patients is therefore not yet public.

Some of the numbers around the product are goals, not results. Vranes told MedCity News the company “hopes to achieve a 74% reduction in acute kidney injuries” and to deliver “a 15 times ROI to hospitals”. We found no published outcome data supporting either figure. MedCity News also reports that the company, founded in 2017, is targeting a Series B funding round.

What we’re watching

  • Publication of the Australian ICU study data, especially how patch readings compare with blood-drawn vancomycin levels.
  • The design and timing of the US pivotal study agreed with the FDA under the breakthrough programme.
  • Whether the multi-analyte platform produces a second sensor target, and what Nutromics discloses about manufacturing the patch at volume.